Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer

Study:

A Phase II Study of AVN944 in Combination With Gemcitabine for the Treatment of Pancreatic Cancer

Rationale:

n/a

Purpose:

The study will find the optimum AVN944 dose to use in combination with gemcitabine in patients with pancreatic cancer and see if the combination of the 2 drugs is more effective for treating pancreatic cancer than using gemcitabine alone.

Study Status: Terminated

Recruiting:
n/a

Condition Intervention Phase
Pancreatic Cancer Drug: AVN944 Phase 2

Verified by Vertex Pharmaceuticals Incorporated September, 2011

Sponsored by: Vertex Pharmaceuticals Incorporated
Information provided by: Vertex Pharmaceuticals Incorporated
ClinicalTrials.gov identifier: NCT00493441

Study Type: Interventional

Study Design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Cleveland Clinic - Taussig Cancer Center
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.